{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T11:41:29Z","timestamp":1789213289935,"version":"build-2803163510"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-025-01709-8","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T09:54:09Z","timestamp":1754042049000},"page":"1097-1105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Current Treatment Strategies for FLT3-Mutated Acute Myeloid Leukemia in Patients not Candidates for Intensive Chemotherapy"],"prefix":"10.1007","volume":"27","author":[{"given":"Alex","family":"Bataller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musa","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"issue":"10393","key":"1709_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023;401(10393):2073\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(23)00108-3","journal-title":"Lancet"},{"issue":"12","key":"1709_CR2","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136\u201352. https:\/\/doi.org\/10.1056\/NEJMra1406184","journal-title":"N Engl J Med"},{"issue":"2","key":"1709_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299\u2013312. https:\/\/doi.org\/10.1038\/s41375-018-0357-9","journal-title":"Leukemia"},{"issue":"22","key":"1709_CR4","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia","year":"2013","unstructured":"Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. N Engl J Med. 2013;368(22):2059\u201374. https:\/\/doi.org\/10.1056\/NEJMoa1301689","journal-title":"N Engl J Med"},{"issue":"23","key":"1709_CR5","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/nejmoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321. https:\/\/doi.org\/10.1056\/nejmoa1516192","journal-title":"N Engl J Med"},{"issue":"1","key":"1709_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41408-024-01143-2","volume":"14","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Borthakur G, Daver N, DiNardo CD, Issa G, Jabbour E, et al. Current status and research directions in acute myeloid leukemia. Blood Cancer J. 2024;14(1):163. https:\/\/doi.org\/10.1038\/s41408-024-01143-2","journal-title":"Blood Cancer J"},{"issue":"12","key":"1709_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/BLOOD.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345\u201377. https:\/\/doi.org\/10.1182\/BLOOD.2022016867","journal-title":"Blood"},{"issue":"5","key":"1709_CR8","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454\u201364. https:\/\/doi.org\/10.1056\/NEJMoa1614359","journal-title":"N Engl J Med"},{"issue":"10388","key":"1709_CR9","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim H-J, Patkowska E, Vrhovac R, \u017d\u00e1k P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10388):1571\u201383. https:\/\/doi.org\/10.1016\/S0140-6736(23)00464-6","journal-title":"Lancet"},{"issue":"22","key":"1709_CR10","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","volume":"116","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Ravandi F, O\u2019Brien S, Cortes J, Faderl S, Garcia-Manero G, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116(22):4422\u20139. https:\/\/doi.org\/10.1182\/blood-2010-03-276485","journal-title":"Blood"},{"issue":"7","key":"1709_CR11","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/nejmoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329. https:\/\/doi.org\/10.1056\/nejmoa2012971","journal-title":"N Engl J Med"},{"issue":"25","key":"1709_CR12","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1182\/BLOOD.2022016963\/1921946\/BLOOD.2022016963.PDF","volume":"140","author":"AH Wei","year":"2022","unstructured":"Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, et al. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood. 2022;140(25):2754\u20136. https:\/\/doi.org\/10.1182\/BLOOD.2022016963\/1921946\/BLOOD.2022016963.PDF","journal-title":"Blood"},{"issue":"1","key":"1709_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or Azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7\u201317. https:\/\/doi.org\/10.1182\/blood-2018-08-868752","journal-title":"Blood"},{"issue":"33","key":"1709_CR14","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1200\/jco.21.02823","volume":"40","author":"TM Kadia","year":"2022","unstructured":"Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, et al. Phase II study of venetoclax added to cladribine plus Low-Dose cytarabine alternating with 5-Azacitidine in older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2022;40(33):3848\u201357. https:\/\/doi.org\/10.1200\/jco.21.02823","journal-title":"J Clin Oncol"},{"issue":"11","key":"1709_CR15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/BLOOD.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135(11):791\u2013803. https:\/\/doi.org\/10.1182\/BLOOD.2019003988","journal-title":"Blood"},{"issue":"13","key":"1709_CR16","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1158\/1078-0432.Ccr-21-3405","volume":"28","author":"M Konopleva","year":"2022","unstructured":"Konopleva M, Thirman MJ, Pratz KW, Garcia JS, Recher C, Pullarkat V, et al. Impact of FLT3 mutation on outcomes after venetoclax and Azacitidine for patients with Treatment-Na\u00efve acute myeloid leukemia. Clin Cancer Res. 2022;28(13):2744\u201352. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-3405","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1709_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41408-023-00911-w","volume":"13","author":"NJ Short","year":"2023","unstructured":"Short NJ, Nguyen D, Ravandi F. Treatment of older adults with FLT3-mutated AML: emerging paradigms and the role of frontline FLT3 inhibitors. Blood Cancer J. 2023;13(1):142. https:\/\/doi.org\/10.1038\/s41408-023-00911-w","journal-title":"Blood Cancer J"},{"issue":"5","key":"1709_CR18","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532\u201342. https:\/\/doi.org\/10.1182\/blood-2002-02-0492","journal-title":"Blood"},{"key":"1709_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1756-8722-4-13","volume":"4","author":"S Takahashi","year":"2011","unstructured":"Takahashi S. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J Hematol Oncol. 2011;4:13. https:\/\/doi.org\/10.1186\/1756-8722-4-13","journal-title":"J Hematol Oncol"},{"issue":"5","key":"1709_CR20","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/sj.onc.1203354","volume":"19","author":"F Hayakawa","year":"2000","unstructured":"Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19(5):624\u201331. https:\/\/doi.org\/10.1038\/sj.onc.1203354","journal-title":"Oncogene"},{"issue":"5","key":"1709_CR21","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1182\/blood.V86.5.1661.bloodjournal8651661","volume":"86","author":"M Gabbianelli","year":"1995","unstructured":"Gabbianelli M, Pelosi E, Montesoro E, Valtieri M, Luchetti L, Samoggia P, et al. Multi-level effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors\/monocytic precursors. Blood. 1995;86(5):1661\u201370. https:\/\/doi.org\/10.1182\/blood.V86.5.1661.bloodjournal8651661","journal-title":"Blood"},{"issue":"21","key":"1709_CR22","doi-asserted-by":"publisher","first-page":"9643","DOI":"10.1158\/0008-5472.Can-05-0422","volume":"65","author":"CH Brandts","year":"2005","unstructured":"Brandts CH, Sargin Bl, Rode M, Biermann C, Lindtner B, Schw\u00e4ble J, et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res. 2005;65(21):9643\u201350. https:\/\/doi.org\/10.1158\/0008-5472.Can-05-0422","journal-title":"Cancer Res"},{"issue":"11","key":"1709_CR23","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.3324\/HAEMATOL.2018.191536","volume":"103","author":"VV Prassek","year":"2018","unstructured":"Prassek VV, Rothenberg-Thurley M, Sauerland MC, Herold T, Janke H, Ksienzyk B, et al. Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. Haematologica. 2018;103(11):1853\u201361. https:\/\/doi.org\/10.3324\/HAEMATOL.2018.191536","journal-title":"Haematologica"},{"issue":"4","key":"1709_CR24","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/ajh.27236","volume":"99","author":"A Bataller","year":"2024","unstructured":"Bataller A, DiNardo CD, Bazinet A, Daver NG, Maiti A, Borthakur G, et al. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol. 2024;99(4):792\u20136. https:\/\/doi.org\/10.1002\/ajh.27236","journal-title":"Am J Hematol"},{"issue":"1","key":"1709_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41408-025-01258-0","volume":"15","author":"FW Hoff","year":"2025","unstructured":"Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, et al. Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the beat AML clinical trial. Blood Cancer J. 2025;15(1):55. https:\/\/doi.org\/10.1038\/s41408-025-01258-0","journal-title":"Blood Cancer J"},{"key":"1709_CR26","unstructured":"SEER NCI SEER*Explorer: An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute; Bethesda, MD. (2025). Available at: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/"},{"key":"1709_CR27","doi-asserted-by":"publisher","unstructured":"Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3 -TKD mutations in AML: the combination matters \u2014 an analysis of 3082 patients. 2008;111(5):2527\u201338. https:\/\/doi.org\/10.1182\/blood-2007-05-091215.An","DOI":"10.1182\/blood-2007-05-091215.An"},{"issue":"18","key":"1709_CR28","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1182\/blood-2010-05-283648","volume":"116","author":"SP Whitman","year":"2010","unstructured":"Whitman SP, Maharry K, Radmacher MD, Becker H, Mr\u00f3zek K, Margeson D, et al. FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. Blood. 2010;116(18):3622\u20136. https:\/\/doi.org\/10.1182\/blood-2010-05-283648","journal-title":"Blood"},{"issue":"11","key":"1709_CR29","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/ajh.24140","volume":"90","author":"T Badar","year":"2015","unstructured":"Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, et al. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol. 2015;90(11):1065\u201370. https:\/\/doi.org\/10.1002\/ajh.24140","journal-title":"Am J Hematol"},{"key":"1709_CR30","doi-asserted-by":"publisher","unstructured":"Li S, Li N, Chen Y, Zheng Z, Guo Y. FLT3-TKD in the prognosis of patients with acute myeloid leukemia: A meta-analysis. Front Oncol. 2023;13\u20132023. https:\/\/doi.org\/10.3389\/fonc.2023.1086846","DOI":"10.3389\/fonc.2023.1086846"},{"key":"1709_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2020-136083","volume":"136","author":"J Sierra","year":"2020","unstructured":"Sierra J, Montesinos P, Thomas X, Gri\u0161kevi\u010dius L, Cluzeau T, Caillot D, et al. Phase 3b study assessing the safety and efficacy of midostaurin in younger and older patients with newly diagnosed, FLT3-Mutated acute myeloid leukemia (AML) who are eligible for 7\u2009+\u20093 or 5\u2009+\u20092 chemotherapy. Blood. 2020;136:23\u20134. https:\/\/doi.org\/10.1182\/blood-2020-136083","journal-title":"Blood"},{"issue":"18","key":"1709_CR32","doi-asserted-by":"publisher","first-page":"5345","DOI":"10.1182\/bloodadvances.2022007223","volume":"6","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Weber D, Krzykalla J, Fiedler W, Wulf G, Salih H, et al. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. Blood Adv. 2022;6(18):5345\u201355. https:\/\/doi.org\/10.1182\/bloodadvances.2022007223","journal-title":"Blood Adv"},{"issue":"7","key":"1709_CR33","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1182\/blood.2021011103","volume":"138","author":"R Itzykson","year":"2021","unstructured":"Itzykson R, Fournier E, Berthon C, R\u00f6llig C, Braun T, Marceau-Renaut A, et al. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood. 2021;138(7):507\u201319. https:\/\/doi.org\/10.1182\/blood.2021011103","journal-title":"Blood"},{"issue":"8","key":"1709_CR34","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/ajh.21458","volume":"84","author":"F Ferrara","year":"2009","unstructured":"Ferrara F, Criscuolo C, Riccardi C, Izzo T, Pedata M, Copia C, et al. FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia and normal karyotype. Am J Hematol. 2009;84(8):532\u20134. https:\/\/doi.org\/10.1002\/ajh.21458","journal-title":"Am J Hematol"},{"issue":"11","key":"1709_CR35","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1038\/s41375-023-01999-6","volume":"37","author":"E Jahn","year":"2023","unstructured":"Jahn E, Saadati M, Fenaux P, Gobbi M, Roboz GJ, Bullinger L, et al. Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Leukemia. 2023;37(11):2187\u201396. https:\/\/doi.org\/10.1038\/s41375-023-01999-6","journal-title":"Leukemia"},{"issue":"24","key":"1709_CR36","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137\u201345. https:\/\/doi.org\/10.1182\/blood.2020004856","journal-title":"Blood"},{"issue":"21","key":"1709_CR37","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144(21):2169\u201373. https:\/\/doi.org\/10.1182\/blood.2024025409","journal-title":"Blood"},{"issue":"21","key":"1709_CR38","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1182\/blood.2024024944","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat VA, et al. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and Azacitidine. Blood. 2024;144(21):2211\u201322. https:\/\/doi.org\/10.1182\/blood.2024024944","journal-title":"Blood"},{"key":"1709_CR39","doi-asserted-by":"publisher","unstructured":"Zhao Y, Zhang X, Ding X, Wang Y, Li Z, Zhao R, et al. Efficacy and safety of FLT3 inhibitors in monotherapy of hematological and solid malignancies: a systemic analysis of clinical trials. Front Pharmacol. 2024;15\u20132024. https:\/\/doi.org\/10.3389\/fphar.2024.1294668","DOI":"10.3389\/fphar.2024.1294668"},{"issue":"18","key":"1709_CR40","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1902688","journal-title":"N Engl J Med"},{"issue":"7","key":"1709_CR41","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","volume":"20","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory\u2009<\u2009em\u2009>\u2009FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):984\u201397. https:\/\/doi.org\/10.1016\/S1470-2045(19)30150-0","journal-title":"Lancet Oncol"},{"issue":"23","key":"1709_CR42","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1182\/blood-2013-01-480228","volume":"121","author":"F Ravandi","year":"2013","unstructured":"Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, et al. Phase 2 study of Azacytidine plus Sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013;121(23):4655\u201362. https:\/\/doi.org\/10.1182\/blood-2013-01-480228","journal-title":"Blood"},{"issue":"9","key":"1709_CR43","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/ajh.25198","volume":"93","author":"M Ohanian","year":"2018","unstructured":"Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, et al. Sorafenib combined with 5-azacytidine in older patients with untreated FLT3-ITD mutated acute myeloid leukemia. Am J Hematol. 2018;93(9):1136\u201341. https:\/\/doi.org\/10.1002\/ajh.25198","journal-title":"Am J Hematol"},{"issue":"8","key":"1709_CR44","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.3324\/haematol.2020.263392","volume":"106","author":"M Swaminathan","year":"2021","unstructured":"Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, et al. A phase I\/II study of the combination of Quizartinib with Azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021;106(8):2121\u201330. https:\/\/doi.org\/10.3324\/haematol.2020.263392","journal-title":"Haematologica"},{"issue":"17","key":"1709_CR45","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1182\/blood.2021014586","volume":"140","author":"ES Wang","year":"2022","unstructured":"Wang ES, Montesinos P, Minden MD, Lee J-H, Heuser M, Naoe T, et al. Phase 3 trial of gilteritinib plus Azacitidine vs Azacitidine for newly diagnosed FLT3mut\u2009+\u2009AML ineligible for intensive chemotherapy. Blood. 2022;140(17):1845\u201357. https:\/\/doi.org\/10.1182\/blood.2021014586","journal-title":"Blood"},{"issue":"22","key":"1709_CR46","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1158\/1078-0432.Ccr-19-0832","volume":"25","author":"J Ma","year":"2019","unstructured":"Ma J, Zhao S, Qiao X, Knight T, Edwards H, Polin L, et al. Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-Mutated acute myeloid leukemia. Clin Cancer Res. 2019;25(22):6815\u201326. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-0832","journal-title":"Clin Cancer Res"},{"issue":"24","key":"1709_CR47","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood.2021014241","volume":"140","author":"M Janssen","year":"2022","unstructured":"Janssen M, Schmidt C, Bruch P-M, Blank MF, Rohde C, Waclawiczek A, et al. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1. Blood. 2022;140(24):2594\u2013610. https:\/\/doi.org\/10.1182\/blood.2021014241","journal-title":"Blood"},{"issue":"4","key":"1709_CR48","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","volume":"106","author":"M Raghuveer Singh","year":"2021","unstructured":"Raghuveer Singh M, Qi Z, RosaAnna D, Antonio C, Vinitha Mary K, Jayant R, et al. Venetoclax combines synergistically with FLT3 Inhibition to effectively target leukemic cells in FLT3-ITD\u2009+\u2009acute myeloid leukemia models. Haematologica. 2021;106(4):1034\u201346. https:\/\/doi.org\/10.3324\/haematol.2019.244020","journal-title":"Haematologica"},{"issue":"1","key":"1709_CR49","doi-asserted-by":"publisher","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","volume":"6","author":"GS Choudhary","year":"2015","unstructured":"Choudhary GS, Al-harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6(1):e1593\u2013e. https:\/\/doi.org\/10.1038\/cddis.2014.525","journal-title":"Cell Death Dis"},{"issue":"35","key":"1709_CR50","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1200\/jco.22.00602","volume":"40","author":"N Daver","year":"2022","unstructured":"Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, et al. Venetoclax plus gilteritinib for FLT3-Mutated relapsed\/refractory acute myeloid leukemia. J Clin Oncol. 2022;40(35):4048\u201359. https:\/\/doi.org\/10.1200\/jco.22.00602","journal-title":"J Clin Oncol"},{"issue":"5","key":"1709_CR51","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41408-022-00670-0","volume":"12","author":"M Yilmaz","year":"2022","unstructured":"Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, et al. Hypomethylating agent and venetoclax with FLT3 inhibitor triplet therapy in older\/unfit patients with FLT3 mutated AML. Blood Cancer J 2022. 2022;12(5):5. https:\/\/doi.org\/10.1038\/s41408-022-00670-0","journal-title":"Blood Cancer J 2022"},{"issue":"6","key":"1709_CR52","doi-asserted-by":"publisher","first-page":"e35813","DOI":"10.1002\/cncr.35813","volume":"131","author":"A Bazinet","year":"2025","unstructured":"Bazinet A, Bataller A, Kadia T, Daver N, Short NJ, Yilmaz M, et al. A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia. Cancer. 2025;131(6):e35813. https:\/\/doi.org\/10.1002\/cncr.35813","journal-title":"Cancer"},{"issue":"2","key":"1709_CR53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41408-021-00410-w","volume":"11","author":"A Maiti","year":"2021","unstructured":"Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, et al. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 2021;11(2):25. https:\/\/doi.org\/10.1038\/s41408-021-00410-w","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"1709_CR54","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1182\/blood-2024-204296","volume":"144","author":"M Yilmaz","year":"2024","unstructured":"Yilmaz M, Muftuoglu M, Short NJ, Loghavi S, Kadia TM, DiNardo CD, et al. Phase I\/II study of quizartinib, venetoclax, and decitabine triple combination in FLT3-ITD mutated AML. Blood. 2024;144(Supplement 1):4263. https:\/\/doi.org\/10.1182\/blood-2024-204296","journal-title":"Blood"},{"issue":"13","key":"1709_CR55","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/jco.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or Refractory\u2009<\u2009i\u2009>\u2009FLT3-Mutated AML. J Clin Oncol. 2024;42(13):1499\u2013508. https:\/\/doi.org\/10.1200\/jco.23.01911","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1709_CR56","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1182\/blood-2024-210891","volume":"144","author":"NJ Short","year":"2024","unstructured":"Short NJ, Loghavi S, Yilmaz M, Karrar O, Jabbour JE, DiNardo CD, et al. Long-Term survival outcomes and cytogenetic\/molecular patterns of relapse in adults with FLT3-Mutated AML receiving frontline triplet therapy with a hypomethylating agent, venetoclax and FLT3 inhibitor. Blood. 2024;144(Supplement 1):220. https:\/\/doi.org\/10.1182\/blood-2024-210891","journal-title":"Blood"},{"issue":"9","key":"1709_CR57","doi-asserted-by":"publisher","first-page":"100534","DOI":"10.1016\/j.modpat.2024.100534","volume":"37","author":"KA Oduro","year":"2024","unstructured":"Oduro KA, Spivey T, Moore EM, Meyerson H, Yoest J, Tomlinson B, et al. Clonal dynamics and relapse risk revealed by High-Sensitivity FLT3-Internal tandem duplication detection in acute myeloid leukemia. Mod Pathol. 2024;37(9):100534. https:\/\/doi.org\/10.1016\/j.modpat.2024.100534","journal-title":"Mod Pathol"},{"issue":"11","key":"1709_CR58","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.3324\/haematol.2024.285057","volume":"109","author":"A Bataller","year":"2024","unstructured":"Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, et al. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica. 2024;109(11):3543\u201356. https:\/\/doi.org\/10.3324\/haematol.2024.285057","journal-title":"Haematologica"},{"issue":"1","key":"1709_CR59","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41408-024-01103-w","volume":"14","author":"Y Yao","year":"2024","unstructured":"Yao Y, Zhou Y, Zhuo N, Xie W, Meng H, Lou Y, et al. Co-mutation landscape and its prognostic impact on newly diagnosed adult patients with NPM1-mutated de Novo acute myeloid leukemia. Blood Cancer J. 2024;14(1):118. https:\/\/doi.org\/10.1038\/s41408-024-01103-w","journal-title":"Blood Cancer J"},{"issue":"3","key":"1709_CR60","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1182\/blood-2005-02-0560","volume":"106","author":"M Alcalay","year":"2005","unstructured":"Alcalay M, Tiacci E, Bergomas R, Bigerna B, Venturini E, Minardi SP, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc\u2009+\u2009AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood. 2005;106(3):899\u2013902. https:\/\/doi.org\/10.1182\/blood-2005-02-0560","journal-title":"Blood"},{"issue":"3","key":"1709_CR61","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","volume":"34","author":"L Brunetti","year":"2018","unstructured":"Brunetti L, Gundry MC, Sorcini D, Guzman AG, Huang Y-H, Ramabadran R, et al. Mutant NPM1 maintains the leukemic state through HOX expression. Cancer Cell. 2018;34(3):499\u2013e5129. https:\/\/doi.org\/10.1016\/j.ccell.2018.08.005","journal-title":"Cancer Cell"},{"issue":"7954","key":"1709_CR62","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al. The Menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615(7954):920\u20134. https:\/\/doi.org\/10.1038\/s41586-023-05812-3","journal-title":"Nature"},{"issue":"1","key":"1709_CR63","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","volume":"43","author":"GC Issa","year":"2024","unstructured":"Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, et al. Menin Inhibition with revumenib for KMT2A-Rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol. 2024;43(1):75\u201384. https:\/\/doi.org\/10.1200\/JCO.24.00826","journal-title":"J Clin Oncol"},{"issue":"24","key":"1709_CR64","doi-asserted-by":"publisher","first-page":"5621","DOI":"10.1182\/bloodadvances.2021005038","volume":"5","author":"M Dennis","year":"2021","unstructured":"Dennis M, Thomas IF, Ariti C, Upton L, Burnett AK, Gilkes A, et al. Randomized evaluation of Quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. Blood Adv. 2021;5(24):5621\u20135. https:\/\/doi.org\/10.1182\/bloodadvances.2021005038","journal-title":"Blood Adv"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01709-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01709-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01709-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T17:02:41Z","timestamp":1758387761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01709-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":64,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["1709"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01709-8","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"18 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.B. No conflicts of interest. Nicholas J. Short has been a consultant for Takeda Oncology, AstraZeneca, Amgen, Novartis, and Pfizer and received research funding from Takeda Oncology, Astellas, and Stemline Therapeutics as well as honoraria from Amgen. Naval G. Daver has received research funding from Astellas Pharma, AbbVie, Genentech, Daiichi Sankyo, Gilead Sciences, ImmunoGen, Pfizer, Bristol Myers Squibb, Trovagene, Servier, Novimmune, Incyte, Hanmi Pharm, Fate Therapeutics, Amgen, Kite Pharma, Novartis, Astex Pharmaceuticals, KAHR, Shattuck, Sobi, GlycoMimetics, and Trillium; has been an advisor for Astellas Pharma, AbbVie, Genentech, Daiichi Sankyo, Novartis, Jazz Pharmaceuticals, Amgen, Servier, Karyopharm Therapeutics, Trovagene, Trillium, Syndax, Gilead Sciences, Pfizer, Bristol Myers Squibb, Kite Pharma, Actinium Pharmaceuticals, Arog Pharmaceuticals, ImmunoGen, Arcellx, and Shattuck; has been a data monitoring committee member for Kartos Therapeutics and Jazz Pharmaceuticals; has been a consultant or board of directors or advisory committee member for Agios, Celgene, Sobi, and STAR Therapeutics; and has received research funding from Karyopham Therapeutics and Newave Pharmaceutical. Musa Yilmaz has received research funding from Daiichi-Sankyo and Pfizer. Hagop M. Kantarjian has received research funding from AbbVie, Amgen, Ascentage Pharma, BMS, Daiichi Sankyo, ImmunoGen, Jazz Pharmaceuticals, and Novartis as well as honoraria from AbbVie, Amgen, Amphista Therapeutics, Ascentage Pharma, Astellas Pharma, Biologix, Curis, Ipsen, KAHR, Novartis, Pfizer, Precision Biosciences, Shenzhen TargetRx, and Takeda Oncology. Farhad Ravandi has received research funding from Amgen, Astex Pharmaceuticals\/Taiho Oncology, BMS\/Celgene, Syos, AbbVie, Prelude, Xencor, Astellas Pharma, and Biomea Fusion as well as honoraria from Amgen, BMS\/Celgene, Syos, AbbVie, and Astellas Pharma; has been a board of directors or advisory committee member for Astex Pharmaceuticals\/Taiho Oncology; and has been a consultant forBMS\/Celgene, Syos, Novartis, AbbVie, AstraZeneca, and Astellas Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}